Trials / Completed
CompletedNCT04098575
A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes
Treatment of T2DM Patients in Germany Receiving Empagliflozin: A Retrospective RWE Study Description of Treatment and Population Characteristics of Type 2 Diabetic Patients in Germany Receiving Empagliflozin: A Retrospective Real-World Evidence (RWE) Study Based on German Registries DPV&DIVE
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 9,571 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Description of the real-life treatment of adult patients with type-2 diabetes mellitus (T2DM) receiving Empagliflozin, comparing the characteristics of patients starting Empagliflozin in three time intervals
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Empagliflozin | drug |
Timeline
- Start date
- 2019-09-16
- Primary completion
- 2019-12-31
- Completion
- 2019-12-31
- First posted
- 2019-09-23
- Last updated
- 2021-03-29
- Results posted
- 2021-03-29
Locations
1 site across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04098575. Inclusion in this directory is not an endorsement.